NORTHAMPTON, MA / ACCESS Newswire / October 15, 2025 / NCDs are the leading cause of death globally, representing a significant burden to people and health care systems. As many as 18 million people d ...
In this study, major adverse cardiovascular event risk varied significantly by medication class, with most protection achieved with sustained treatment with glucagon-like peptide-1 receptor agonists ...
Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback